Humanized IgG1 monoclonal antibody targeting CD20 on pre‑B and mature B lymphocytes, inducing B‑cell depletion via complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and apoptosis while sparing plasma cells; administered intravenously every 6 months.
Humanized IgG1 monoclonal antibody targeting CD20 on pre-B and mature B lymphocytes that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis while sparing plasma cells; administered intravenously every 6 months.
Anti‑CD20 mAb binds CD20 on B cells and induces killing via complement-dependent cytotoxicity (CDC), antibody‑dependent cell‑mediated cytotoxicity (ADCC) by Fc receptor–bearing effector cells, and apoptosis.
Fully human IgG1 monoclonal antibody targeting CD20 on pre‑B and mature B lymphocytes, inducing B‑cell depletion via complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and apoptosis while sparing plasma cells; administered subcutaneously monthly.
Fully human IgG1 monoclonal antibody targeting CD20 on pre-B and mature B cells; binding induces B-cell depletion predominantly via complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and apoptosis, while sparing CD20-negative plasma cells.
Ofatumumab binds CD20 on B cells and kills them via complement-dependent cytotoxicity (CDC) and Fc-mediated ADCC by immune effector cells; it may also induce apoptosis upon crosslinking.
CD20xCD3 T-cell engaging bispecific humanized monoclonal antibody (2:1 format) that redirects cytotoxic T cells to eliminate CD20-positive B cells.
A CD20xCD3 bispecific monoclonal antibody that simultaneously binds CD20 on B cells and CD3 on T cells, forming an immune synapse to activate and redirect cytotoxic T cells to kill CD20-positive B cells.
Bispecific CD20xCD3 antibody bridges T cells to CD20+ cells, activating T-cell cytotoxicity (perforin/granzyme release and apoptosis) to kill CD20-expressing B cells.
Type II anti-CD20 glycoengineered monoclonal antibody used as a lead-in to deplete CD20-positive B cells.
Glycoengineered humanized IgG1 type II anti‑CD20 monoclonal antibody that binds CD20 on B cells. Afucosylated Fc increases affinity for FcγRIIIa, enhancing antibody‑dependent cellular cytotoxicity and phagocytosis, and it also induces direct caspase‑independent cell death. Net effect is potent depletion of CD20‑positive B cells.
Binds CD20 on B cells; the afucosylated Fc engages Fc gamma RIIIa on effector cells to trigger NK-cell ADCC and macrophage phagocytosis, and the type II antibody also induces direct caspase-independent cell death (with limited CDC).
Autologous, genetically engineered TCR-T cell therapy expressing an HLA-A*11:01–restricted T cell receptor specific for the KRAS G12V neoantigen; administered after lymphodepletion with a single IV infusion to recognize KRAS G12V peptides on tumor HLA-A*11:01, expand (with low-dose IL-2 support), and mediate cytotoxic killing of tumor cells in advanced solid tumors.
Autologous T cells genetically engineered to express an HLA-A*11:01–restricted TCR specific for the KRAS G12V neoantigen; after lymphodepletion and low-dose IL-2 support, the infused cells recognize KRAS G12V peptides presented on tumor HLA-A*11:01, expand, and mediate cytotoxic killing of mutant KRAS–expressing tumor cells.
Engineered TCR-T cells recognize the KRAS G12V peptide presented by HLA-A*11:01 on tumor cells and directly induce apoptosis via perforin/granzyme release and Fas–FasL signaling.